How to Cite
Abstract
В обзоре приведены основные биохимические характеристики, данные по экспрессии в норме и при опухолевом росте, описаны основные ткани-продуценты двух опухолеассоциированных маркеров—СА125 и белка эпидидимиса человека НЕ4. Обсуждаются результаты многоцентровых рандомизированных скрининговых исследований с использованием СА125 для выявления РЯ и мониторинга больных. Приведены данные литературы, касающиеся клинико-диагностической значимости нового серологического опухолеассоциированного белка НЕ4 в дифференциальной диагностике и мониторинге больных раком яичников как дополнительного (к СА125) и самостоятельного серологического маркера.References
Алексеева М. Л., Андреева Е. Н., Новиков Е. А. и др. Определение антигенов СА125, СА19-9 и РЭА у гинекологических больных для дифференциальной диагностики и оценки эффективности оперативного лечения и последующего мониторинга // Акуш. и гин. - 1995. - № 5. - С. 25-28.
Алексеева М. Л., Фанченко Н. Д., Новиков Е. А. и др. Опухолевые маркеры в гинекологии // Акуш. и гин. - 1995. - № 5. - С. 35-37.
Ахмедова С.А. Совершенствование клиниколабораторной концепции использования СА 125 у больных раком яичников: Дис.. канд. биол. наук. - М. - 2003. - 130 с.
Гончаренко В. Н. Метаболическая коррекция про- и антиоксидантных систем при гнойном перитоните. Автореферат дис.канд. мед. наук. - М. - 1997. - 36 с.
Клинические рекомендации. Онкология. 2-е издание // Под ред. В.И. Чиссова, С.Л. Дарьяловой - М.: ГЭОТАР-Медиа. - 2009. - 560 с.
Корнеева И.А., Новикова Е.Г., Сергеева Н.С. Современный взгляд на маркерный рецидив рака яичников // Росс. онкол. жур. - 2010. - № 2. - С. 54-57.
Корнеева И. А., Новикова Е. Г., Сергеева Н. С. Опухолевые маркеры СА125 и НЕ4 в диагностике, лечении и мониторинге рака яичников // Женское здоровье. - 2011. - № 12. - C. 48-58.
Мари Э., Вуд, Пол А. Банн. Секреты гематологии и онкологии. / Под ред. Ю. Н. Токарева, А. Е. Бухны - М.: Бином. - 1997. - 560 с.
Опухолевые маркеры и их исследование. // Сб. по материалам фирмы Immunotech, сер. Info Line. - 1998. - 28 с.
Семенова А. И. Мониторинг эффективности лечения и выявление рецидивов с помощью биомаркеров // Практ. онкол. - 2011. - Т. 12, № 4. - C. 171-177.
Сергеева Н. С., Ермошина Н. В., Мишунина М. П. и др. Использование опухолеассоциированных маркеров для диагностики и контроля за эффективностью терапии у больных с распространенным раком яичников. Пособие для врачей М.: ФГУ МНИОИ им. П. А. Герцена Росздрава. - 2009. - 26 с.
Сергеева Н.С., Маршутина Н.В. Опухолеассоциированные маркеры в скрининговых программах, направленных на активное выявление рака яичников: реальность, проблемы и перспективы. // Практ. онкол. - 2010. - Т. 11. - № 2. - С. 110-119.
Anastasi E., Marchei G.G.,Viggiani V. et al. HE4: a new potential early biomarker for the recurrence of ovarian cancer // Tunor Biol. - 2010. - Vol. 31. - P. 113-119.
Anastasi E., Granato T., Marchei G.G. et al. Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women // Ibid. - 2010. - Vol. 31 - P. 411-415.
Bafna S., Kaur S., Batra S.K. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells // Oncogene. - 2010. - Vol. 29. - P. 2893-2904.
Bast R. C. Jr., Freeney M., Lazarus H. et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. // J. Clin. Invest. - 1981. - Vol. 68. - P. 1331-1337.
Bast R.C. Jr, Xu F.J., Yu Y.H. et al. CA 125: the past and the future // Int. J. Biol. Markers. - 1998. - Vol. 13. - P. 179-187.
Barbieri R. L. CA125 and endometriosis // Gynec. Obstet. - 1987. - Vol. 16. - P. 103-108.
Bingle L., Singleton V., Bingle C.D. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms // Oncogene. - 2002. - Vol. 21. - P. 2768-2773.
Blalock T.D., Spurr-Michaud S.J., Tisdale A.S. et al. Functions of MUC16 in corneal epithelial cells // Invest. Ophthalmol. Vis. Sci. - 2007. - Vol. 48. - P. 4509-4518.
But I., Gorisek B. Preoperative value of CA 125 as a reflection of tumor grade in epithelial ovarian cancer // Gynecol. Oncol. - 1996. - Vol. 63. - P. 166-172.
Clauss A., Lilja H., Lundwall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein // Biochem. J. - 2002. - Vol. 368. - P. 233-242.
Dandekar A. M., Robinson E. A., Appellla E. et al. Complete sequence analysis of cDNA clones encoding rat whey phosphoprotein: homology to a protease inhibitor // Proc. Natl. Acad. Sci. USA. - 1982. - Vol. 79. - P. 3987-3991.
Devine P.L., McGuckin M. A., Quin R. J., et al. Predictive value of the combination of serum markers, CA125 CASA and TPS in ovarian cancer // Int. J. Gynecol. Cancer. - 1995. - № 5. - P. 170-178.
Drapkin R., von Horsten H.H., Lin Y. et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas // Cancer Res. - 2005. - Vol. 65. - P. 2162 -2169.
Einhorn N., Sjövall K., Knapp R.C. et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer // Obstet Gynecol. - 1992. - Vol. 80. - P. 14-18.
Escudero J.M., Auge J.M., Filella X. et al. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases // Clin.Chem. - 2011. - Vol. 57. - P. 1534-1544.
Fehm T., Beck E., Valerius T. et al. CA 125 elevations in patients with malignant lymphomas // Tumour Biol. - 1998. - Vol. 19. - P. 283-289.
Galgano M.T., Hampton G.M., Frierson H.F. Jr. et al. Comprehensive analysis of HE4 expression in normal and malignant human tissues // Mod. Pathol. - 2006. - Vol. 19. - P. 847-853.
HE4 ARCHITECT System. Instructions for HE4 reagent kit. 2009. Abbott Laboratories.
Heise Ju., Diziol P. Tumor markers: Their uses and significance in clinical practice - Germany: Boehringer Mannheim GmbH. - 1991. - 85 p.
Heitz A.P.M., Odicino F., Maisonneuve P. et al. Carcinoma of the ovary // Int. J. Gynecol. Obstet. - 2006. - Vol. 95. - Р. 161-192.
Hirose T., Ohta S., Sato I. et al. Adachi M. Tuberculous pleuro-peritonitis showing increased levels of CA125. // Nihon Kyobu Shikkan Gakkai Zasshi. - 1997. - Vol. 35. - P. 196-200.
Holcomb K., Vucetic Z., Miller M.C. et al. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women // Amer J. Obstet Gynecol. - 2011. - Vol. 205. - P. 358-363.
Hough C.D., Sherman-Baust C.A., Pizer E.S. et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer // Cancer Res.- 2000. - Vol. 60. - P. 6281-6287.
Hynninen J., Auranen A., Dean K. et al. Serum HE4 Profile During Primary Chemotherapy of Epithelial Ovarian Cancer. // Int. J. Gynecol. Cancer. - 2011. - Vol. 21 (9). - P. 1573-1578.
Inaba N., Negishi Y., Fukasawa I. et al. Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen // Tumor Biol. - 1995. - Vol. 16. - P. 345-352.
Jacob F., Meier M., Caduff R. et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting // Gynecol. Oncol. - 2011. - Vol. 121. -P. 487-491.
Jacobs I., Davies A.P., Bridges J. et al. Prevalence screening for ovarian cancer in postmenopausal women by CA125 measurement and ultrasonography // B.M.J. - 1993. - Vol. 306. - P. 1030-1032.
Jacobs I.J., Menon U. Progress and challenges in screening for early detection of ovarian cancer // Mol. Cell Proteomics. - 2004. - Vol. 3. - P. 355-366.
Jellum E., Andersen A., Lund-Larsen P. et al. Experiences of the Janus Serum Bank in Norway // Environ Health Pe rspect. - 1995. - Vol. 103. - P. 85-88.
Kabawat S. E., Bast R. C., Bhan A. K. et al. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody that recognized common surface antigens of human ovarian tumors of serous, endometrioid and clear cell types // Amer. J. Clin. Pathol. - 1983. - Vol. 79. - P. 781-785.
Karlan B.Y., Platt L.D. The current status of ultrasound and color Doppler imaging in screening for ovarian cancer // Gynecol. Oncol. - 1994. - Vol. 55. - P. 28-33.
Kirchhoff C., Habben I., Ivell R. et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. // Biol. Reprod. - 1991. - Vol. 45. - P. 350-357.
Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity // Nature. - 1975. - Vol. 257. - P. 95.
Kong S.Y., Han M.H., Yoo H.J. et al. Serum HE4 Level is an Independent Prognostic Factor in Epithelial Ovarian Cancer // http://www.springerlink.com/content/r57355k162526760/?MUD=MP
Kui Wong N., Easton R.L., Panico M. et al. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125 // J. Biol. Chem. - 2003. -Vol. 278. - P. 28619-28634.
Latimer J. A., Beng C. G., Davy M. U. For stage III epithelial ovarian cancer the initial level of expression of CA125 does not correlate with survival in women who respond to treatment // Int. J. Gynecol. Oncol. - 1996. - № 6. -P. 380-384.
Lenhard M., Stieber P., Hertlein L. et al. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses // PubMed PMID: http://www.springerlink.com/content/r57355k162526760/?MuD=MP
Liu P.Y., Alberts D.S., Monk B.J. et al. An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy / /J.Clin. Oncol. - 2007. - Vol. 25. -P. 3615-3620.
Marell A. R., Llana B. F., Alvarez A. et al. CA125 and non gynaecological benign diseases // Int. Symp. CA125: Ten years later. San-Remo, Italy. - 1993. - P. 1717-1720.
Masahashi T., Matsuzawa M., Ohsawa O. et al. Serum CA125 levels in patients with endometriosis: Changes in the CA125 levels during menstruation // Obstet. Gynecol. - 1988. - Vol. 72. - P. 328-331.
Meden H., Fattahi-Meibodi A. CA 125 in benign gynecological conditions // Int. J. Biol. Markers. - 1998. -Vol. 13. - P. 231-237.
Menon U., Scates S., Macdonald N. et al. Risk of ovarian cancer algorithm (ROCA) for the early detection of ovarian cancer // Tumor Biol. - 2000. - Vol. 21. - P. 15.
Menon U., Skates S.J., Lewis S. Et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer // J. Clin. Oncol. - 2005. - Vol. 23. -P. 7919-7926.
Menon U., Gentry Maharaj A., Hallett R. et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) // Lancet Oncol. - 2009. - Vol. 10. - P. 327-340.
Molina R. Agusti C. Mañe J.M. et al. CYFRA 21-1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels // Int. J. Biol. Markers. - 1994. - Vol. 9. -P. 96-101.
Molina R., Escudero J.M., Augé J.M. et al. HE4 a novel tumor marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases // Tumor Biol. - 2011. - Vol. 32. - P. 1087-95.
Montagnana M., Lippi G., Ruzzenente O. Et al. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. // J. Clin. Lab. Anal. - 2009. -Vol. 23 (5). - P. 331-335.
Moore R.G., Miller M.C., Eklund E.E. et al. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age // Amer. J. Obstet Gynecol. - 2011. - P. 1-7.
Moore R.G., Miller M.C., Disilvestro P. et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass // Obstet Gynecol. - 2011. - Vol. 118. - P. 280-288.
Mozas J., Castilla J.A., Jimena P. et al. CA-125 in the diagnosis of acute pelvic inflammatory disease // Int. J. Gynecol. Obstet. - 1994. - Vol. 44. - P. 53-57.
Nap M. Immunohistochemistry of CA 125. Unusual expression in normal tissues, distribution in the human fetus and questions around its application in diagnostic pathology // Int. J. Biol. Markers. - 1998. - Vol. 13. -P. 210-215.
Nustad K., Onsrud M., Jansson B. еt al. CA125 - epitopes and molecular size // J. Biological Markers. - 1998. -Vol. 13. - P. 196-199.
O’Brien T. J., Tanimoto H., Konishi I. et al. More than 15 tears of CA125: What is known about the antigen, its structure and its function // J. of Biological Markers. - 1998. - Vol. 13. - P. 188-195.
O’Brien T.J., Beard J.B., Underwood L.J. et al. The CA 125 gene: an extracellular superstructure dominated by repeat sequences // Tumor Biol. - 2001. - Vol. 22. -P. 348-366.
O’Brien T.J., Beard J.B., Underwood L.J. et al. The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure // Tumor Biol. - 2002. - Vol. 23. - P. 154 -169.
Ono K., Tanaka T., Tsunoda T. et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis // Cancer Res. - 2000. - Vol. 60. - P. 5007-5011.
Paek J., Lee S.H., Yim G.W. et al. Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer // Europ. J. Obstet Gynecol. Reprod. Biol. - 2011. -Vol. 158. - P. 338-342.
Park Y., Lee J.H., Hong D.J. et al. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases // Clin. Biochem. - 2011. - Vol. 44. - P. 884 -888.
Perez B.H., Gipson I.K. Focus on Molecules: human mucin MUC16 // Exp. Eye Res. - 2008. - Vol. 87. - P. 400 -401.
Ruggeri G., Bandiera E., Zanotti L. et al. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm // Clin. Chim. Acta. - 2011. - Vol. 412. - P. 1447-1453.
Ruibal A., Encabo G., Martinеz-Miralles E. et al. CA125 seric levels in non malignant pathologies // Bull. Cancer. - 1984. - Vol. 71. - P. 145-146.
Rustin G.J., Marples M., Nelstrop A.E. et al. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels // J. Clin. Oncol. - 2001. - Vol. 19. - P. 4054-4057.
al-Sayer H., al-Bader A., Hussein T. et al. A profile of tumor markers in the population of Kuwait // Anticancer Res. - 1999. - Vol. 19. - P. 2369-2372.
Schummer M., Ng V. L. V., Baumgarner R. E. et al. Comparative hybridization of an array of 21500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas // Gene - 1999. - Vol. 238. - P. 375 -385.
Sedlaczek P., Frydecka I., Gabrys M. et al. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma // Cancer (Philad). - 2002. - Vol. 95. - P. 1886-1893.
Seki K., Kikuchi Y., Uesato T. et al. Increased serum CA125 levels during the first trimester of pregnancy // Acta Obstet et Gynecol. Scand. - 1986. - Vol. 65. -P. 583-586.
Steffensen K.D., Waldstram M., Brandslund I. et al. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients // Int. J. Gynecol. Cancer. - 2011. - Vol. 21. - P. 1040-1047.
Van Gorp T., Cadron I., Despierre E. et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm // Brit. J. Cancer. - 2011. - Vol. 104. - P. 863-870.
Wang K., Gan L., Jeffery E., Gayle M. et al. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray // Gene. - 1999. - Vol. 229. - P. 101-108.
Wilke G., Hinney B., Rath W. et al. CA-125 serum level in early pregnancy follow hMG/hCG stimulated and unstimulated cycles // Geburtshilfe Frauenheilkd. - 1990. -Vol. 50. - P. 941-946.
Yin B.W., Lloyd K.O. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16 // J. Biol. Chem. - 2001. - Vol. 276. - P. 27371 -27375.
Yin B.W., Lloyd K.O. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. MUC16 mucin gene // Int. J. Cancer. - 2002. -Vol. 98. - P. 737-740.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...